Tevi-Benissan Carol, Okeibunor Joseph, du Châtellier Gaël Maufras, Assefa Afework, Biey Joseph Nsiari-Muzenyi, Cheikh Dah, Eshetu Messeret, Anya Blanche-Philomene, Dao Halima, Nasir Yusuf, Akanmori Bartholomew Dicky, Mihigo Richard
Immunization and Vaccines Development Programme, Family and Reproductive Health Cluster.
Polio Eradication Programme, Office of the Regional Director, World Health Organization (WHO) Regional Office for Africa, Brazzaville, Congo.
J Infect Dis. 2017 Jul 1;216(suppl_1):S66-S75. doi: 10.1093/infdis/jiw616.
The Polio Eradication and Endgame Strategic plan outlines the phased removal of oral polio vaccines (OPVs), starting with type 2 poliovirus-containing vaccine and introduction of inactivated polio vaccine in routine immunization to mitigate against risk of vaccine-associated paralytic polio and circulating vaccine-derived poliovirus. The objective includes strengthening routine immunization as the primary pillar to sustaining high population immunity. After 2 years without reporting any wild poliovirus (July 2014-2016), the region undertook the synchronized switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) as recommended by the Strategic Advisory Group of Experts on Immunization. Consequently the 47 countries of the World Health Organization (WHO) African Region switched from the use of tOPV to bOPV within the stipulated period of April 2016. Planning started early, routine immunization was strengthened, and technical and financial support was provided for vaccine registration, procurement, destruction, logistics, and management across countries by WHO in collaboration with the United Nations Children's Fund (UNICEF) and partners. National commitment and ownership, as well as strong coordination and collaboration between UNICEF and WHO and with partners, ensured success of this major, historic public health undertaking.
《脊髓灰质炎根除及终结战略计划》概述了分阶段停用口服脊髓灰质炎疫苗(OPV)的计划,首先停用含2型脊髓灰质炎病毒的疫苗,并在常规免疫中引入灭活脊髓灰质炎疫苗,以降低疫苗相关麻痹性脊髓灰质炎和循环疫苗衍生脊髓灰质炎病毒的风险。目标包括加强常规免疫,将其作为维持高人群免疫力的主要支柱。在连续两年未报告任何野生脊髓灰质炎病毒(2014年7月至2016年)之后,该地区按照免疫战略咨询专家组的建议,同步从三价OPV(tOPV)转换为二价OPV(bOPV)。因此,世界卫生组织(WHO)非洲区域的47个国家在2016年4月规定的期限内从使用tOPV转换为bOPV。规划工作提前启动,常规免疫得到加强,WHO与联合国儿童基金会(UNICEF)及合作伙伴协作,为各国的疫苗注册、采购、销毁、物流和管理提供技术和资金支持。国家的承诺和自主权,以及UNICEF与WHO之间以及与合作伙伴之间的强有力协调与合作,确保了这项重大的历史性公共卫生事业取得成功。